Cubicin Outcomes Registry and Experience (CORE) Methodology

American Journal of Medicine

Volumn 120, Issue 10 SUPPL. 1, 2007, Pages

  Rolston, Kenneth V I ^a   Segreti, John ^b   Lamp, Kenneth C ^c   Friedrich, Lawrence V ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

Bacteremia; Daptomycin; Right sided endocarditis; Skin and skin structure infections

Indexed keywords

DAPTOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; DRUG EFFICACY; DRUG INFORMATION; DRUG RESEARCH; HUMAN; OSTEOMYELITIS; OUTCOMES RESEARCH; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; SKIN INFECTION; UNITED STATES;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; REGISTRIES; SKIN DISEASES, INFECTIOUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34648816823     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.07.008     Document Type: Article

References (2)

1. Arbeit R.D., Maki D., Tally F.P., Campanaro E., and Eisenstein B.I. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38 (2004) 1673-1681
2. Fowler Jr. V.G., Boucher H.W., Corey R., et al., S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355 (2006) 653-656